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ABSTRACT
INTRODUCTION: Colorectal cancer is the most commonly diagnosed gastrointestinal cancer worldwide. 
For patients without metastatic disease, surgery is the first option used with curative intention, for stage I 
disease the adequate treatment consists only of surgical excision. In stage III additional adjuvant chemo-
therapy post-surgery is recommended. In stage II colon cancer, adjuvant treatment remains controversial.
We aim to stratify patients according to different criteria, identify those with recurrence within the first 
year post last cycle of adjuvant chemotherapy and discuss those primary results.
MATERIALS AND METHODS: a total of 52 patients who were subject to curative resection of stage II 
and III colon adenocarcinoma and who were administrated 5 FU based adjuvant chemotherapy were includ-
ed and were followed for a period of two years. Data analysis was performed.
RESULT: After a mean of 2 years of follow-up, recurrence was identified in 16 patients. None of stage II 
patients (n=6) and 3 patients in stage III (n=16) experienced recurrence. Patients with Nx cancer (n=30) 
were detached in separate group. Thirteen of them experienced recurrence (9 patients had relapse within 6 
months after surgery – defined as synchronous metastatic disease).
CONCLUSION: Surgery remains the cornerstone of treatment for the majority of colon patients. The se-
lection of optimal chemotherapy for each patient is a complex process and there is a practice evidence gap 
which remains a significant problem. Our results for relapse are comparable with the reported ones world-
wide. The reports suggest that there is still lack of evidence in the adjuvant colon cancer chemotherapy 
worldwide.
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INTRODUCTION
Colorectal cancer (CRC) is the most commonly 
diagnosed gastrointestinal cancer worldwide (nearly 
1.4 million new cases in 2012); it is the fourth most 
common cause of cancer-related death, following 
lung, stomach and liver cancer (1). In Bulgaria for 
2012 there have been 2370 newly diagnosed colon 
cancer and 1664 rectal cancers cases. The total num-
ber of registered patients is 29995 (2).
The currently used TNM staging system for 
colorectal cancer is version 7 and is based on sever-
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al criteria: the extent of primary tumor invasion into 
intestinal wall (T), the number of involved metastat-
ic regional lymph nodes (N), and the presence of dis-
tant metastasis (M). The oncological management of 
colon cancer patients is based on the initial clinical 
staging of the disease. For patients without metastat-
ic disease (cM0), surgery is the first option, used with 
curative intention. It is actually considered that for 
stage I disease the adequate treatment consists only 
of surgical excision of the primary tumor and the re-
gional lymph nodes. The surgery should excise the 
tumor with wide margins and regional lymphade-
nectomy such that at least 12 lymph nodes are avail-
able for pathologic evaluation. For lesions above the 
rectum, resection of the tumor with a minimum 
5-cm margin of grossly negative colon is considered 
adequate. Laparoscopic colectomy approaches have 
been developed and appear to be equally effective 
staging and therapeutic approaches to open colecto-
my, with modest decreases in hospital stay and pain 
medication use and improved cosmetic results (3). 
Variations in the use of radiotherapy (RT) alone or 
combined with chemotherapy and in surgical tech-
nique only for rectal cancer have been investigated 
in attempts to improve local control rates. Numer-
ous randomized controlled studies of both preoper-
ative and postoperative RT alone have demonstrated 
no improvement in survival; at best, there has been a 
small decrease in the rate of local recurrence.
In stage III additional adjuvant chemotherapy 
post-surgery is recommended as standard of care. 
Oxaliplatin based chemotherapy is now emerging 
as the new standard of care in adjuvant treatment 
of stage III colon cancer. Adjuvant chemotherapy 
for stage III colon cancer (lymph node involvement) 
with 5-FU plus Levamisole (historical) or 5-FU plus 
Leucovorin reduced the incidence of recurrence by 
41% (p < 0.001) in a number of large prospective ran-
domized trials. The MOSAIC study in Europe ran-
domized 2 200 patients (40% stage II, 60% stage III) 
to receive 5-FU infusion and Leucovorin without 
or with Oxaliplatin (FOLFOX) (4,5). In stage II co-
lon cancer, adjuvant treatment remains controversial 
– according to the current guidelines of the Amer-
ican Society of Clinical Oncology adjuvant chemo-
therapy is not routinely recommended in all stage II 
cases, but could be considered in several subgroups 
of patients, including poorly differentiated histology 
(G3), T4 lesions, bowel perforation at presentation or 
inadequately sampled regional lymph nodes (<12). A 
meta-analysis of five trials involving about 1,000 pa-
tients showed a statistically insignificant difference 
in 5-year survival rates of 82% versus 80%, treated 
versus untreated, respectively, for patients with stage 
II disease. The QUASAR group did show a 3% sur-
vival advantage at 5 years for FU/L over observation 
in a trial that enrolled >3 200 patients. There was no 
survival advantage for the 40% of stage II patients en-
rolled in the MOSAIC trial. The ASCO recommends 
against the routine use of chemotherapy in stage II 
colon cancer (6-8).
Oxaliplatin based chemotherapy (FOLFOX) 
shows effectiveness including after radical liver re-
section in stage IV patients (pseudoadjuvant thera-
py) – 35.4% vs. 28.1% without recurrence in a 3 years 
follow-up (9).
Cetuximab and Panitumumab are monoclonal 
antibodies that target the epidermal growth factor 
receptor (EGFR) and have been approved for use in 
advanced, refractory colorectal cancer (There is no 
evidence in adjuvant aspect). Multiple clinical trials 
have convincingly established that mutations in RAS 
render these two antibodies ineffective in colorectal 
cancer. Consequently, Cetuximab and Panitumum-
ab should only be used in RAS wild-type colorectal 
cancer. Both have single agent activity resulting in 
response rates of 10% to 15% in third-line therapy in 
RAS wild-type cancers.
Currently, the relative 5 year survival rates for 
all stages colon cancer is reported as about 62%, but 
in cases of localized disease it increases to 90%. For 
stage IIA it is 66.5%, stage IIB – 58.6%, stage IIC – 
37.3%, respectively IIIA – 73.1%, IIIB – 46.3%, IIIC 
– 28% (10).
In our study we collected data for patients with 
colon cancer stage II and III, who underwent surgery, 
adjuvant chemotherapy in our institution – Univer-
sity hospital “St. Marina” and agreed to collection of 
serum/plasma (for the needs of further tests, planned 
additionally as a second trial, aiming to identify dif-
ferent potential predictive/prognostic markers). As a 
first step we aim to stratify patients according to dif-
ferent criteria, identify those with recurrence within 
the first year post last cycle of adjuvant chemothera-
py and discuss those primary results.
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METHODS
Patient selection
We conducted a prospective non-experimental 
clinical study of a total of 52 patients who were sub-
ject to curative resection of stage II and III colon ad-
enocarcinoma. The patients were followed for a pe-
riod of 2 years after surgery which was performed 
at the University Hospital “St. Marina” from Au-
gust 2011 to November 2013. Prior to inclusion in 
our study we obtained ICF for collection of biologi-
cal material (plasma/serum) from all patients willing 
to participate.
We included patients with colon cancer stage II 
and III as per AJCC, 7th ed. who underwent radical 
surgery in our hospital; there was no residual disease 
or compromised edges post-surgery and patients 
have completed 5-FU based adjuvant chemothera-
py. We obtained plasma/serum after last cycle of ad-
juvant chemotherapy and patients started follow-up 
regularly (every 3-6 months) with CT/PET-CT un-
til progression or 2 year of follow-up. Follow-up time 
was measured from date of surgery until date of pro-
gression or 2 years.
Clinical and pathologic features
We collected the following clinical and patho-
logic data: demographical data (age at initial stag-
ing, sex, etc), date of surgery, extent of surgery, tumor 
characteristics – localization, histology, grade of dif-
ferentiation and TNM classification, total number of 
histologically examined lymph nodes and type of ad-
juvant chemotherapy, date of last cycle.
Follow-up and recurrence of disease
Recurrence was defined as appearance of any 
new lesion(s) or local recurrence (anastomotic or re-
gional). Patients were followed for 2 years after date 
of surgery or until recurrence was documented. The 
follow-up included: a colonoscopy one year follow-
ing end of adjuvant chemotherapy, a CT of the tho-
rax and abdomen every 3-6 months or upon presen-
tation of clinical symptoms.
Statistical methods
Data analysis was performed with the statistical 
analyzer SPSS for Windows, ver. 21. Descriptive sta-
tistics was used. Categorical features were summa-
rized with frequencies and percentages.
RESULTS
Stage II
Six patients with stage II disease were includ-
ed in our study. Their data was summarized in Table 
1. All patients had moderately differentiated adeno-
carcinomas (G2). The total number of dissected and 
histologically examined lymph nodes was at least 12. 
All patients had T3 tumors and were treated with 5 
FU based adjuvant chemotherapy (n=4 Mayo Clinic, 
n=2 De Gramont). After 2 years of follow-up surgery 
none of them experienced recurrence.
Stage III
Sixteen patients with stage III colon cancer 
were included in our study. Their data was summa-
rized in Table 1. One patient had well differentiated 
tumor (G1), 12 patients had moderately differentiat-
ed tumors (G2) and 3 patients had poorly differen-
tiated (G3) tumors. Fifteen patients had T3 tumors 
and 1 had T4a tumor. The total number of dissect-
ed and histologically examined lymph nodes was at 
least 12. All patients were treated with 5 FU based ad-
juvant chemotherapy (n = 9 FOLFOX4, n = 4 Mayo 
Clinic, n = 1 De Gramont and n = 1 monotherapy 
Capecitabine). After a mean of 2 years of follow-up 
3 of them experienced recurrence (18.7%) (Table 2). 
These 3 patients had all received FOLFOX4 as adju-
vant chemotherapy; 2 of them had G2 tumors and 
one had a G3 tumor.
Nx group (no description of lymph node involve-
ment possible due to lack of data)
Thirty patients with Nx cancer were included 
in our study. Their data was summarized in Table 1. 
One patient had a well differentiated tumor (G1), 26 
patients had moderately differentiated tumors (G2) 
and 3 patients had poorly differentiated (G3) tumors. 
The total number of dissected and histologically ex-
amined lymph nodes was less than 12. Six patients 
had T2 tumors, 19 patients had T3 tumors and 5 pa-
tients had T4a tumor. All patients were treated with 
5 FU based adjuvant chemotherapy (n = 4 FOLF-
OX4, n = 12 Mayo Clinic, n = 11 De Gramont and 
n = 3 Capecitabine monotherapy). After a mean of 
2 years of follow-up 13 of them experienced recur-
rence (43.3%). Nine patients had a recurrence within 
6 months after surgery (30% of Nx group). Two of the 
other 4 patients who had recurrence (G1 and G2 tu-
mors) have received Mayo Clinic as adjuvant chemo-
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Table 1.  Summary of clinical, pathologic and treatment features for all patients
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therapy, one (G3 tumor) received De Gramont and 
one (G2 tumor) received FOLFOX4.
Data for recurrence, evaluation methods of recur-
rence and location of recurrence is shown on Table 2.
DISCUSSION
The results of this study, analyzing the data of a 
total of 6 patients with stage II colon cancer at high 
risk, demonstrated a two-year recurrence rate of 0%. 
The stage III colon cancer population of 16 patients, 
as expected, had a much higher two-year recurrence 
rate of 18.7%, with most recurrences occurring with-
in the first year after surgery. Compared with other 
studies, the findings for risk of recurrence for stage II 
and III colon cancer are similar to those in our study 
(11).
We have separated patients with Nx disease in 
a different group. As we expected, those 30 patients 
within this group had a much higher two-year re-
currence rate of 43.3%; again most recurrences oc-
curred within the first year after surgery. Accord-
ing to Cunliffe et al. synchronous metastases can be 
two or more in number, detected for a period up to 
6-month-period postoperatively (12). Thus we con-
sidered patients with recurrence within 6 months af-
ter surgery (30% of Nx group) to have had synchro-
nous metastasis.
Prognostic factors are particularly useful in the 
context of stage II colon cancer, where benefits of cy-
totoxic adjuvant therapy are more controversial than 
in stage III disease (13).
In our study for all patients the mean number of 
histologically examined lymph nodes was less than 
10 due to the large number of Nx group patients. Sev-
eral studies focusing on stage II disease suggest that 
patients with fewer total lymph nodes dissected at 
surgery encounter more often micrometastases and 
have higher risk for recurrence (14,15). Others stud-
ies do not confirm those findings (16).
We consider the diagnosis of Nx disease a poor 
prognostic factor as those patients could receive sub-
optimal adjuvant therapy; they also have increased 
recurrence rate that could imply the need of inten-
sified follow-up, especially during the first year af-
ter surgery of the primary tumor. Variety of adjuvant 
chemotherapy regimens have been used in this Nx 








Time to recurrence (N)
Under 6 months 





Time to recurrence (mounts, mean ± SD) 5.5 (± 4.487) Min. 1, Max. 12




















Table 2. Recurrence, evaluation methods of recurrence and location of recurrence
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ysis of the MOSAIC trial did not show a significant 
DFS or OS benefit of FOLFOX over 5FU/LV for pa-
tients with high-risk stage II disease (including pa-
tients with less than 10 lymph node examined) (4,5).
CONCLUSION
Surgery remains the cornerstone of treatment 
for the majority of colon patients. The selection of 
optimal chemotherapy for each patient is a complex 
process and there is a practice evidence gap which 
remains a significant problem. There are differenc-
es in the chemotherapy regimen pattern in the dif-
ferent institutions, regions and countries. The results 
suggest that there is still lack of evidence in the adju-
vant colon cancer chemotherapy worldwide (1). The 
identification of accurate predictive and prognostic 
markers will help clinicians in choosing appropriate 
use of adjuvant chemotherapy in patients with colon 
cancer which we plan to study in further research.
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